Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP7374 in adults
NCT02366962Phase 3Completed
- Sponsor
- UMN Pharma Inc.
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ASP7374 in influenza, sponsored by UMN Pharma Inc. Primary endpoint: Safety assessed by adverse events at Day 29. Started Feb 2015; status: completed.
02
Drugs
ASP7374
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02366962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366962.